At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 469 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine (specific dose not specified in criteria or arms section)AI-extracted
Key inclusion· 3
- ✓Age 60 years or older
- ✓Scheduled for cardiac surgery with planned ICU admission for at least 24 hours
- ✓Same-day surgical admission
Key exclusion· 9
- ✕Blind, deaf, or unable to speak English
- ✕Greater than 2 days of ICU admission in the month prior to current surgery
- ✕Renal and liver failure requiring dialysis or Child-Pugh score >5
- ✕Active substance abuse, psychotic disorder, or homelessness affecting follow-up
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS): A Randomized Placebo-controlled Trial
In Brief
A Phase 3 clinical trial evaluating Dexmedetomidine and Placebo for Postoperative Delirium and 2 related conditions. Completed, enrolled 469 participants across 1 site.
Detailed Summary
This study aims to determine whether, compared with placebo, the nighttime administration of a intravenous dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in extubated post-cardiac surgical patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Delirium, Sleep, Anesthesia
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartMar 2017
Primary CompletionFeb 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedAug 5, 2016
Enrollment StartMar 6, 2017
Primary CompletionFeb 11, 2022
Study CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.9 years ago
Interventions
Dexmedetomidinedrug
Dexmedetomidine
Placebodrug
Placebo